Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study☆
Introduction
Salivary gland neoplasms account for approximately 5% of all head and neck cancers. The majority arise in the parotid gland, and of these 25% are malignant. Of those tumors which arise in the other salivary glands, 50% are malignant.1 Malignant epithelial tumors of the salivary glands can be classified histologically as mucopeidermoid carcinoma (MEC), adenoid cystic carcinoma (ACC), carcinoma ex pleomorphic adenoma, acinic cell carcinoma, polymorphous low grade adenocarcinomas and a collection of other rare tumor types.2 Acinic cell carcinoma, adenoid cystic carcinoma and carcinoma ex pleomorphic adenoma are thought to arise from the intercalated duct of the salivary gland, whereas salivary duct carcinoma, squamous cell carcinoma and mucoepidermoid carcinoma are thought to arise from the salivary excretory duct.3
Surgical resection is the primary treatment of these neoplasms at initial diagnosis. Radiation therapy is usually reserved for patients with advanced disease with inadequate margins or with poor prognostic features such as perineural invasion or anaplastic histology.4
Chemotherapy, in general, has been reserved for patients with incurable salivary neoplasms. Typical response rates are in the order of 15–30% and are usually short lived. The most active single agents include cisplatin, cyclophosphamide, doxorubicin and 5-fluorouracil. Therefore, there is a definite need to look for more active agents in this disease.
Her2/neu is a protooncogene that is located on chromosome 17q. Amplification of Her2/neu or overexpression of its protein exists in a number of human carcinomas including breast, ovary, endometrial, thyroid and salivary neoplasms and has been associated with a poor prognosis in these patients.5, 6, 7, 8 Salivary carcinoma overexpression of Her2/neu assayed by immunostaining techniques has been reported prior to this study in mucoepidermoid carcinoma (30–38%), adenoid cystic carcinoma (56%) and terminal duct carcinoma (24%), suggesting that dysregulation of Her2/neu as a contributing factor is not histology specific.5, 9
Herceptin® (Trastuzumab), a humanized murine monoclonal antibody directed against Her2/neu protein has been studied extensively in breast cancer. There are no prior trials of Herceptin in patients with advanced salivary gland neoplasms. We report here the first such trial in these patients.
Section snippets
Patients and methods
Patients with locally advanced or metastatic salivary gland tumors were enrolled in an institutional review board (IRB) approved phase II study of Herceptin used as a single agent. All patients signed IRB approved consents prior to enrollment. Entry criteria included a histological diagnosis of salivary gland tumor, incurable disease on the basis of unresectable local disease or distant metastasis, maximum of two regimens of cytotoxic chemotherapy, ECOG performance status of 0 or 1,
Results
Patient characteristics are listed in Table 1. Fourteen patients were enrolled between October 1999 and August 2001. The study was closed early when it became clear that the majority of patients screened did not overexpress Her2/neu suggesting a very limited role for Herceptin in salivary gland tumors.10 There were 10 males and 4 females with a mean age of 60 (range 44–80). The majority of the tumors were of parotid origin (9/14) with the predominant histology being adenocarcinoma (7/14). Five
Discussion
Malignant tumors of salivary gland origin are rare neoplasms. There are approximately 2000 cases reported annually in the USA. Many pathologic subtypes have been defined as distinct clinicopathologic and biologic entities. Salivary duct carcinoma, intermediate and high grade mucoepidermoid carcinoma, undifferentiated carcinoma and carcinoma ex pleomorphic adenoma are clinically aggressive and may recur or metastasize quickly. Adenoid cystic carcinoma is often controlled locally, however
References (17)
- et al.
c-erbB-2/neu oncogene and Ki-67 analysis in the assessment of palatal salivary gland neoplasms
Otolaryngol Head Neck Surg
(1995) - et al.
Malignant salivary tumors—analysis of prognostic factors and survival
Head Neck Surg
(1986) Salivary neoplasmsoverview of a 35-year experience with 2,807 patients
Head Neck Surg
(1986)- et al.
Malignant tumors of the salivary glands
(1996) Management of malignant tumors of the salivary glands
Oncology (Huntingt)
(1998)- et al.
Amplification and overexpression of HER-2/neu in carcinomas of the salivary glandcorrelation with poor prognosis
Cancer Res.
(1994) - et al.
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
Science
(1989) - et al.
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes
Br J Cancer
(1991)
Cited by (219)
Salivary gland carcinoma: Towards a more personalised approach
2024, Cancer Treatment ReviewsHER2-targeted therapies for salivary gland cancers
2024, Oral OncologySystemic therapies for salivary gland carcinoma (excluding adenoid cystic carcinoma): REFCOR recommendations by the formal consensus method
2023, European Annals of Otorhinolaryngology, Head and Neck DiseasesMutational and immunologic Landscape in malignant Salivary Gland Tumors harbor the potential for novel therapeutic strategies
2022, Critical Reviews in Oncology/HematologyTraitements systémiques des cancers des glandes salivaires (hors carcinomes adénoïdes kystiques) : recommandations REFCOR par consensus formalisé
2023, Annales Francaises d'Oto-Rhino-Laryngologie et de Pathologie Cervico-Faciale
- ☆
Supported in part by a grant from Genentech and support from the generosity of our patients and their families.